Vaccine Production Core

疫苗生产核心

• 批准号: 7952753
• 负责人: Fred Robert Frankel
• 金额: $ 8.9万
• 依托单位: IMMUNE DISEASE INSTITUTE, INC.
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-08-11 至 2010-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7952753
• 关键词: AIDS Vaccines; Acquired Immunodeficiency Syndrome; Adolescent; Adult; Alanine; Antibiotics; Attenuated; Bacteria; CD8B1 gene; Characteristics; Clinical Trials; Cloning; Complex; Consensus; Culture Media; Disease; DsRed; Engineering; Epidemic; Future; Gagging; Genes; Genetic; Growth; HIV; HIV Infections; HIV/SIV vaccine; Human; Immune response; Life; Listeria; Listeria monocytogenes; Macaca mulatta; Maintenance; Methods; Monkeys; Mus; Organism; Preparation; Proteins; Recombinants; Role; SIV; Safety; Solutions; T-Lymphocyte; Vaccination; Vaccine Production; Vaccines; cell mediated immune response; design; immunogenicity; microorganism; novel vaccines; oral vaccine; research study; response; simian human immunodeficiency virus; vector

New HIV infections worldwide occur every 25 seconds and a vaccine is the only long-term solution to this epidemic. A new attenuated strain of Listeria monocytogenes is a vector with potential for use as an oral vaccine against the disease. In Project 1 of this application several recombinants of attenuated Listeria that individually express various foreign genes will be generated by standard cloning methods: the flourochrome DsRed, for use in mouse experiments, SIV gag and nef, 89.6 tat, and the envelope genes of SHIV 89.6P and SHIV 1157ip for use in trials in juvenile and adult rhesus monkeys, and new recombinants of the attenuated Listeria that express a consensus-type clade B env sequence, JRFL, and a clade B'C env sequence from Beijing for potential use in future human studies. This core project is designed to (1) generate amounts of these recombinant bacteria commensurate with the needs of the various projects using them and (2) to assure the authenticity of the organisms by characterizing the preparations with respect to their genetic correctness, their lack of reversion to wild-type, their safety and immunogenicity in mice, and their expression of the desired heterologous proteins. We will also explore the ability of a synthetic medium to be used for the growth of the organisms so as to eliminate from future preparations, if possible, the complex, poorly characterized molecules that currently are used in their growth medium.

全球每25秒就有新的艾滋病毒感染病例发生，疫苗是唯一的长期解决方案 这场流行病。一种新的单核细胞增生李斯特菌减毒株是一种具有潜在的 用作对抗这种疾病的口服疫苗。在本申请的项目1中， 将通过标准方法产生单独表达各种外源基因的减毒李斯特菌 克隆方法：荧光染料DsRed，用于小鼠实验，SIV gag和nef，89.6 达特，以及SHIV 89.6P和SHIV 1157ip的包膜基因，用于在青少年和成年人中进行试验 恒河猴，和新的重组减毒李斯特菌，表达共识型 进化枝B env序列、JRFL和一个来自北京的进化枝B 'C env序列 人类研究这个核心项目的目的是（1）产生大量的这些重组 细菌与使用它们的各种项目的需要相称，以及（2）确保 生物体的真实性，通过表征制剂的遗传 正确性、它们不回复到野生型、它们在小鼠中的安全性和免疫原性，以及它们的 表达所需的异源蛋白。我们还将探索合成人 用于微生物生长的培养基，以便从未来的制备中消除，如果 可能的是，目前用于其生长的复杂的、特征不明确的分子 介质